ReCode Therapeutics
1140 O'Brien Drive
Menlo Park, CA 94025
United States
Tel: 408-585-1700
Website: https://recodetx.com/
Email: info@recodetx.com
About ReCode Therapeutics
The Why Behind Our Work
We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.
Therapeutic Areas of Focus
Cystic fibrosis
Primary ciliary dyskinesia
Certain cancers and central nervous system (CNS) diseases
Power the Next Wave of Genetic Medicine
We are one of the rare companies whose innovations are poised to fundamentally shift an entire class of medicine.
Join us as we advance our pipeline into clinical development and scale ReCode’s next-generation genetic medicines delivery platform and pipeline.
52 articles about ReCode Therapeutics
-
ReCode Therapeutics to Participate in Upcoming August Investor Conferences
8/3/2021
ReCode Therapeutics today announced that Company leadership will host 1x1 meetings at two upcoming virtual investor conferences in August: Canaccord Genuity 41 st Annual Growth Conference. Dates: August 10 – 12, 2021
-
ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference
7/30/2021
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference,
-
ReCode Therapeutics to Present at William Blair Biotech Focus Conference 2021
7/8/2021
ReCode Therapeutics today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
ReCode Therapeutics to Participate in Upcoming June Investor Conferences
6/14/2021
ReCode Therapeutics today announced that the Company will participate in two upcoming virtual investor conferences in June.
-
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
6/11/2021
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP ™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS).
-
ReCode Therapeutics to Present Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
5/24/2021
ReCode Therapeutics to Present Preclinical Data Using SORT-LNP ™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
-
ReCode Therapeutics to Participate in Upcoming Investor Conferences - Feb 16, 2021
2/16/2021
ReCode Therapeutics™, a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, announced that members of the executive team will be participating in three upcoming virtual investor conferences.
-
ReCode Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
1/11/2021
ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.
-
ReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial Officer
10/13/2020
ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO
-
ReCode Therapeutics Strengthens Leadership Team With New Appointments
9/9/2020
- Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC - Brandon Wustman, Ph.D. promoted to Senior Vice President, R&D MENLO PARK, Calif. & DALLAS--( BUSINESS WIRE )-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for life-limiting respiratory diseases, today announced two key executive appointments. Mu